Kapellerová A, Sustrová M, Cingelová D, Kuková Z, Krovinová A
II. detská klinika LF UK, Bratislava.
Cesk Pediatr. 1993 Feb;48(2):103-5.
The authors treated with Biostim (Roussel Uclaf Co., France) 20 children aged 3 to 15 years with relapsing and chronic diseases of the respiratory system. A favourable clinical effect was observed in 45% and improvement in 40% of the patients. In the investigated immunological indicators the response to treatment Biostim was manifested in the antibody immunity by a reduction of IgE values (P < 0.01) and of IgM (P < 0.05). As to cellular immunity, there was a significant increase of the phagocytic activity (P < 0.05). The tolerance of the preparation was very good.
作者用法国罗素优克福公司生产的“必思添”（Biostim）对20名3至15岁患有复发性和慢性呼吸系统疾病的儿童进行治疗。45%的患者观察到良好的临床效果，40%的患者病情有所改善。在所研究的免疫指标中，对“必思添”治疗的反应在抗体免疫方面表现为IgE值降低（P<0.01）和IgM降低（P<0.05）。至于细胞免疫，吞噬活性显著增加（P<0.05）。该制剂的耐受性非常好。
